Skip to main content

Table 4 Characteristics of children retained in care, dead or LTFU

From: A 17 year experience of attrition from care among HIV infected children in Nnewi South-East Nigeria

Characteristics In care or referred LTFU Dead p-value
Clinical stage at enrolment (n = 1101)
 WHO stage 1 75(13.3) 44(9.9) 3(3.2)  
 WHO stage 2 161(28.5) 105(23.6) 9(9.7)  
 WHO stage 3 297(52.7) 247(55.6) 53(57.0)  
 WHO stage 4 31(5.5) 48(10.4) 28(30.1)  
Duration of care (n = 564) (n = 457) (n = 93)  
  < 6 months 9(1.6) 192(42.0) 42(45.2)  
 6 months to < 12 months 14(2.5) 66(14.4) 13(14.0)  
 1 to < 5 years 165 (29.3) 137(30.0) 21(22.6)  
 5 to < 10 years 227 (40.2) 48(10.5) 12(12.9)  
 10 to < 15 years 145 (25.7) 14(3.1) 5(5.4)  
  ≥ 15 years 4 (0.7) 0 (0.0) 0 (0.0)  
 Median care duration (IQR) in years 6.9(6.3) 0.7(2.8) 0.6(3.3) < 0.001*
Age at enrolment (years) (n = 564) (n = 457) (n = 93)  
  < 1 year 79(14.0) 84(18.4) 20(21.5)  
 1 to < 5 years 198(35.1) 189(41.4) 36(38.7)  
 5 to < 10 years 163(28.9) 121(26.5) 23(24.7)  
 10 to < 15 years 124(22.0) 63(13.8) 14(15.1)  
 Median enrolment age (IQR) in years 5.1(7.7) 3.8(6.0) 2.6(6.3) < 0.001*
Age at last visit (years) (n = 564) (n = 457) (n = 93)  
  < 1 year 2(0.4) 43(9.4) 10(10.8)  
 1 to < 5 years 33(5.9) 152(33.3) 30(32.3)  
 5 < 10 years 104(18.4) 139(30.4) 25(26.9)  
 10 to < 15 years 201(35.6) 105(23.0) 26(28.0)  
  > =15 years 224(39.7) 18(3.9) 2(2.2)  
 Median last visit age (IQR) in years 14.1(5.4) 6.0(7.7) 6.3(9.4) < 0.001*
Use of ARV
 Yes 538 (95.4) 258(56.5) 70(75.3)  
 No 26(4.6) 199(43.5) 23(24.7)  
Enrolment and ARV initiation interval (months) n = 538 n = 258   
Mean ± SD 12.9 ± 25.84 6.7 ± 17.45 7.8 ± 16.51 < 0.001
ARV initiation and last visit interval (years) n = 538 n = 258 n = 70  
  < 1 year 40(7.4) 144(55.8) 39(55.7)  
 1 to < 5 years 197(36.6) 72(27.9) 20(28.6)  
 5 to < 10 years 199(37.0) 33(12.8) 7(10.0)  
 10 years< 15 years 102 (19.0) 9 (3.5) 4 (5.7)  
Median ARV initiation and last visit interval (IQR) 5.7(6.1) 0.6(3.0) 0.6(2.8) <  0.001*
  1. LTFU loss to follow-up, IQR interquartile range, SD standard deviation, ARV anti-retrovirals
  2. *Statistically significant Kruskal-Wallis test, Statistically significant one-way ANOVA